It may be hypothesized that dual PI3K/mTOR inhibitor NVP-BEZ235 is a more potent antitumor agent against RCC than the mTOR kinase inhibitor PP242 and selective mTORC1 inhibitor Rapamycin. Here, MTOR is linked to renal cell carcinoma.